Brief: Pliant Therapeutics Q2 Net Income USD -43.3 Million

Pliant Therapeutics

07/08/2025 21:05

Overview

Pliant discontinues bexotegrast development in IPF due to adverse events

Q2 net loss narrows to $43.3 mln, aided by workforce restructuring

Research and development expenses fall 29% due to BEACON-IPF discontinuation

Outlook

Pliant Therapeutics focuses on oncology after IPF program discontinuation

Company restructuring aims to extend cash runway

Result Drivers

BEACON-IPF DISCONTINUATION - Discontinuation of bexotegrast in IPF led to reduced R&D expenses

WORKFORCE RESTRUCTURING - Strategic restructuring completed to extend cash runway, reducing administrative costs

ONCOLOGY FOCUS - Ongoing Phase 1 trial of PLN-101095 in solid tumors, with data expected by year-end

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$43.30 mln
Q2 Operating Expenses
-$45.59 mln
Q2 Operating Income
-$45.59 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Pliant Therapeutics Inc is $3.00, about 43.7% above its August 6 closing price of $1.69

Press Release: ID:nGNX2ZWSZ8

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)